Effectiveness and tolerability of early initiation of combined lipid-lowering therapy included simvastatin and fenofibrate vs simvastatin alone in patients with acute coronary syndrome and type 2 diabetes mellitus with hypertriglyceridemia

Main Article Content

O. A. Koval
S. V. Romanenko
P. O. Kaplan
T. V. Pugach


The aim – to determine the effect of early statin-fibrate combination therapy on correction of atherogenic dyslipidemia and apoprotein metabolism in acute coronary syndrome (ACS) patients with type 2 diabetes mellitus.
Materials and methods. Patients (n=60) with T2DM, hypertriglyceridemia (HTG), were randomly assigned in 5–21 days of onset of any form of ACS to receive a combination of simvastatin 40 mg and fenofibrate 145 mg daily or simvastatin 40 mg daily during 12 months. At 3 and 12 months after randomization, we measured levels of absolute and percent changes in the total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol
(HDL-C), non high density lipoprotein cholesterol (Non-HDL-C), TG levels, percentage of patients achieving and retaining complex lipid goals according to ESC 2011 guideline, absolute and percent changes in apoproteins A1 and B (apoA1 and apoB) levels, аpoB/аpoA1 ratio and lipoprotein (a) (Lp(a)), HbA1, uric acid and common safety measurements (ALT/AST, creatinine levels, eGFR).
Results and discussion. Nonsignificant TC levels decrease all over the study without intergroup difference (p>0.05) was seen with the same results as for LDL-C levels in both groups. Constant decrease of Non-HDL-C to 2.88 (2.41–3.38) mmol/L with combined treatment (р=0.042 with index level) vs evident tendency to its increase 3.46 (2.87–4.44) mmol/l in the only statin group in 12 months was registered with intergroup difference (р=0.047). The constant greater extent of TG lowering in combined treatment was seen both at 3 months (р=0.037), and at 12 months (р=0.007) with significant intergroup changes: р=0.035 and р=0.03 respectively. Combination therapy has increased аpoA1 to 1.45 (1.29–1.62) g/L (р<0.00001 with initial), decrease аpoB level to 0.87 (0.71–0.97) g/L (p>0.05) and аpoB/аpoA1 relation to 0.57 (0.51–0.74) (р=0.0005 compared to initial). In statin group initial moderate increase of аpoA1 in 3 months changed by its prominent decrease to 1.32 (1.18–1.43) g/L (р=0.02 with initial data), аpoB increase to 0.97 (0.77–1.14) g/L along with ароВ/ароА1 relation 0.74 (0.56–0.87) with intergroup difference ароВ/ароА1 relation (р=0.047) at the study end. Combined therapy provided significant decrease of Lp(a) content compared to initial level all over the study: in 3 months (р=0.0004) and in12 months (р=0.005) unlike slight elevation during the study in simvastatin group (p>0.05). The combined therapy treatment with fenofibrate had led to highly significant decrease of uric acid levels just in 3 months of treatment (р<0.0001 from baseline) and this level withheld all the study period (р=0.002) without any changes in the control group. Combined therapy was associated with slight but significant (р=0.0006) decline of renal function during the study, not seen in the statin group without treatment withdrawal and requirements of replacement therapy.
Conclusion. The combined therapy with simvastatin and fenofibrate in patients with type 2 diabetes mellitus and HTG initiated early after ACS for one year period is safe, effectively correctes atherogenic dyslipidemia, normalizes apolipoprotein metabolism and decreases Lp(a), uric acid levels unlike simvastatin therapy alone.

Article Details


atherogenic dyslipidemia, acute coronary syndrome, diabetes mellitus, treatment, phenofibrate, simvastatin


Baigent C. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) // Eur. Heart J.– 2020.– Vol. 41.– P. 111–188. doi: https://doi.org/10.1093/eurheartj/ehz455.

Bittner V., Bertolet M., Barraza R. Felix and the BARI 2D Study Group Comprehensive Cardiovascular Risk Factor Control Improves Survival The BARI 2D Trial // J. Amer. Coll. Cardiol.– 2015.– Vol. 66.– P. 765–773.

Catapano A. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the

European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR) // Eur. Heart J.– 2016.– Vol. 37.– P. 2999–3058. doi: https://doi.org/10.1093/eurheartj/ehw272.

Chacón Piñero A., Nogales-Asensio J.M., Martı́nez-Carapeto A. et al. Current Management of Hyperlipidemia in Patients Discharged With a Diagnosis of Acute Coronary Syndrome // Rev. Esp. Cardiol.– 2016.– Vol. 69 (1).– P. 75–85.

Cordero A., Moreno-Arribas J., Bertomeu-Gonzalez V. et al. Low levels of high-density lipoprotein cholesterol are independently associated withacutecoronary heart disease in patients hospitalized for chest pain // Rev. Esp. Cardiol.– 2012.– Vol. 65 (4).– P. 319–325.

Ferrari R. et al.Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia // Eur. Heart J.– 2016.– Vol. 18 (Suppl. C). C2–C12. The Heart of the Matter. doi: https://doi.org/10.1093/eurheartj/suw009.

Gencer B., Kronenberg F., Stroes E.S., Mach F. Lipoprotein(a): therevenant // Eur. Heart J.– 2017.– Vol. 38.– P. 1553–1560. doi: https://doi.org/10.1093/eurheartj/ehx033.

Grundy S.M., Arai H., Barter P. et al. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary // Atherosclerosis.– 2014.– Vol. 232.– P. 410–413.

Joshi P.H., Martin S.S., Blumenthal R.S. The remnants of residual risk // JACC.– 2015.– Vol. 65, N 21.– P. 2276–2278.

Koh K.K., Quon M.J., Han S.H. et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia // J. Am. Coll. Cardiol.– 2005.– Vol. 45.– P. 1649–1653.

Kuroda M., Shinke T., Sakaguchi K. et al. Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy a prospective observational study // J. Am. Coll. Cardiol.– 2015.– Vol. 8.– P. 800–811.

Miller M., Cannon C.P., Murphy S.A. et al. Impact of trigly­­­ceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 Trial // J. Am. Coll. Cardiol.– 2008.– Vol. 51.– P. 724–730.

Muhlestein J.B., Heidi T. May, Jensen J.R. et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia The DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study // J. Am. Coll. Cardiol.– 2006.– Vol. 48.– P. 396–401.

Schwartz G.G., Abt M., Bao W. et al. PHDFasting triglyce­­rides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins // J. Am. Coll. Cardiol.– 2015.– Vol. 65.– P. 2267–2275.

Yusuf S., Hawken S., Ounpuu S., on behalf of the INTER­­HEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study // Lancet.– 2004.– Vol. 364.– P. 937–952.

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) // Eur. Heart J.– 2017.– Vol. 00.– P. 1–66. doi: https://doi.org/10.1093/eurheartj/ehx393.

Most read articles by the same author(s)